JUN and cancer: Identifying inhibitors specific to ubiquitin‐proteasome pathways is usually of great interest for cancer treatment because aberrations in the components of this pathway are commonly observed in many cancers and uncontrolled growth of cancer cells can result either from stabilization of oncoproteins (e.g., c‐jun) or increased degradation of tumor suppressor proteins (e.g., p53).